Immunotherapy in Japan falls into two regulatory paths. Approved products, such as CAR-T cell therapies, are regulated as approved medicines under the pharmaceutical law. Self-pay cell treatments offered by clinics, including many NK cell and dendritic cell treatments, are regulated under the Act on the Safety of Regenerative Medicine, and the clinic must file a plan for each one. This article explains the classification and the regulatory difference.
Three names, two regulatory paths
Immunotherapy is a broad term. Three cell-based treatments come up most often in Japan:
- CAR-T therapy modifies a patient's T cells to recognize a specific protein on tumor cells and then returns the modified cells to the body.
- NK cell therapy expands the patient's or a donor's natural killer cells and returns them.
- Dendritic cell therapy uses immune cells that present antigens to other immune cells. In clinic offerings it often appears as a vaccine.
CAR-T is a manufactured, approved product class in Japan. NK and dendritic cell treatments are usually clinic-run procedures. The difference in names hides a difference in the legal path, and that path determines what the clinic must file and what public information exists about the treatment.
Two evidence categories in Japan
The National Cancer Center Japan's Cancer Information Service describes immunotherapy in two broad groups. The first is immunotherapy whose effectiveness has been proven, which the service describes as limited to some areas. Its examples on the page are immune checkpoint inhibitors. The second is immunotherapy whose effectiveness has not been proven, which includes free-clinic (jiyū shinryō) immunotherapy. For that second group, the page says the treatment has not been proven effective and is not established medical treatment. It also advises that anyone considering a free-clinic immunotherapy should discuss its effectiveness, safety and cost with their treating doctor.

The page is a classification guide.
CAR-T under the pharmaceutical law
CAR-T products are approved medicines in Japan. The first CAR-T product to be approved there, tisagenlecleucel (Kymriah), was approved in March 2019 for relapsed or refractory B-cell acute lymphoblastic leukemia and large B-cell lymphoma, according to a 2019 trade report on the approval. Other CAR-T products have since been approved, and each approval is limited to its labeled indication and conditions.
The Safety Act excludes approved regenerative medicine products when they are used within their approved conditions, and it excludes clinical trials. A CAR-T product used as approved is therefore not handled as a clinic's self-pay regenerative treatment. A clinic that modifies cells for a use outside an approved product is a different case. Under the Enforcement Regulations, cells that have been genetically modified fall into Class I, the highest risk class.
NK and dendritic cell treatments under the Safety Act
When a clinic offers NK or dendritic cell treatment outside an approved product, the Safety Act applies. The clinic must file a plan for that technique, and the plan's class depends on the cells and their use:

- Class I applies when the cells come from a person other than the recipient, when the cells were genetically modified, or in certain other cases. Class I plans require review by a specially certified committee and a 90-day waiting period after filing before treatment may begin.
- Class II applies to cultured stem cells, cultured cells used to rebuild or repair body structure or function, and cells used for a non-homologous purpose.
- Class III covers the remaining techniques. Many autologous immune cell treatments fall here, because the patient's own cells are expanded without genetic modification and used for a purpose that is not tissue rebuilding.
These classes come from Articles 2 and 3 of the Enforcement Regulations. The class for a given clinic's treatment is set by the filed plan. A plan is a legal filing, and it does not establish that the treatment works.
Side-by-side comparison
| CAR-T (approved products) | NK cell treatment (clinic) | Dendritic cell treatment (clinic) | |
|---|---|---|---|
| Legal path | Pharmaceutical law, as approved | Safety Act, plan filed by clinic | Safety Act, plan filed by clinic |
| Cell source | Patient's T cells, genetically modified | Patient's or donor's NK cells | Patient's or donor's immune cells |
| Genetic modification | Yes | Not usual; check the plan | Not usual; check the plan |
| Typical class under the Safety Act | Not applicable as approved | Class III for autologous use; Class I for donor cells | Depends on cell source and use |
| Evidence status in Japan | Approved medicine with labeled indications | Free-clinic immunotherapy, described as not proven | Not addressed in this article |
The table summarizes classification and legal status, not clinical results.
What to ask a clinic
- Is this an approved product, a clinical trial, or a self-pay regenerative treatment under the Safety Act?
- If it is a self-pay treatment, which class is it filed under, and which committee reviewed the plan?
- Are the cells the patient's own or from a donor, and were they genetically modified?
- What human evidence supports use for my specific condition, and who reviews the outcome?

If the answers do not match, send the clinic's name and the treatment description to our advisors, and we will check whether the clinic has filed a provision plan for that treatment. The wider regulatory framework is covered on our how Japan regulates regenerative medicine page, and our NK cell therapy article covers the NK-specific classes.
Frequently asked questions
Are CAR-T therapies in Japan the same as clinic immunotherapy?
No. CAR-T products are approved medicines under the pharmaceutical law, while clinic immunotherapy is a self-pay treatment under the Safety Act. The two paths have different filing and approval requirements.
What class are dendritic cell treatments in Japan?
The class depends on the cell source and how the cells are used. A donor-derived or genetically modified treatment is Class I. An autologous, unmodified treatment is generally Class III, and a non-homologous use may be Class II. The filed plan decides.
Does a filed plan mean an immunotherapy works?
No. Filing shows the clinic completed the legal procedure. Effectiveness is a separate question, and the National Cancer Center Japan describes free-clinic immunotherapy as not proven effective.
Why does CAR-T involve genetic modification?
CAR-T uses a gene that gives the T cell a receptor designed to recognize a specific tumor-cell protein. The Safety Act treats genetically modified cells as a higher-risk category when a clinic uses them outside an approved product.
Does the legal path change what a patient should ask?
Yes. Approved products come with a labeled indication, while a self-pay treatment under the Safety Act comes with a filed plan. Ask which of the two applies before comparing anything else.
Sources: Japan Act on the Safety of Regenerative Medicine (Act No. 85 of 2013), Art. 2 and Enforcement Regulations, Arts. 2–3 (e-Gov text); National Cancer Center Japan, Cancer Information Service, "Immunotherapy: More Detail," updated 6 November 2025 (ganjoho.jp); trade report on Japan's March 2019 approval of tisagenlecleucel (thepharmaletter.com, search-result summary); general immunology background on CAR, NK and dendritic cells (general consensus, no URL). Checked November 2026; MHLW (or the relevant body) publications prevail.
Medical disclaimer: This site provides general information only and does not constitute medical advice; whether any treatment is suitable for you must be decided by a doctor after an in-person consultation.